Institut Pasteur, Université Paris Cité, CNRS UMR 3525, INSERM UA12, Comparative Functional Genomics Group, Paris, 75015, France.
Université Paris Cité, Institut Cochin, INSERM, CNRS, F-75014, Paris, France.
Reprod Biol Endocrinol. 2024 Feb 10;22(1):21. doi: 10.1186/s12958-023-01181-8.
Biomarker identification could help in deciphering endometriosis pathophysiology in addition to their use in the development of non invasive diagnostic and prognostic approaches, that are essential to greatly improve patient care. Despite extensive efforts, no single potential biomarker or combination has been clinically validated for endometriosis.Many studies have investigated endometriosis-associated biological markers in specific tissues, but an integrative approach across tissues is lacking. The aim of this review is to propose a comprehensive overview of identified biomarkers based on tissue or biological compartment, while taking into account endometriosis phenotypes (superficial, ovarian or deep, or rASRM stages), menstrual cycle phases, treatments and symptoms.We searched PubMed and Embase databases for articles matching the following criteria: 'endometriosis' present in the title and the associated term 'biomarkers' found as Medical Subject Headings (MeSH) terms or in all fields. We restricted to publications in English and on human populations. Relevant articles published between 01 January 2005 (when endometriosis phenotypes start to be described in papers) and 01 September 2022 were critically analysed and discussed.Four hundred forty seven articles on endometriosis biomarkers that included a control group without endometriosis and provided specific information on endometriosis phenotypes are included in this review. Presence of information or adjustment controlling for menstrual cycle phase, symptoms and treatments is highlighted, and the results are further summarized by biological compartment. The 9 biological compartments studied for endometriosis biomarker research are in order of frequency: peripheral blood, eutopic endometrium, peritoneal fluid, ovaries, urine, menstrual blood, saliva, feces and cervical mucus. Adjustments of results on disease phenotypes, cycle phases, treatments and symptoms are present in 70%, 29%, 3% and 6% of selected articles, respectively. A total of 1107 biomarkers were identified in these biological compartments. Of these, 74 were found in several biological compartments by at least two independent research teams and only 4 (TNF-a, MMP-9, TIMP-1 and miR-451) are detected in at least 3 tissues with cohorts of 30 women or more.Integrative analysis is a crucial step to highlight potential pitfalls behind the lack of success in the search for clinically relevant endometriosis biomarkers, and to illuminate the physiopathology of this disease.
生物标志物的鉴定有助于解析子宫内膜异位症的病理生理学,此外还可用于开发非侵入性的诊断和预后方法,这对于极大地改善患者护理至关重要。尽管进行了广泛的研究,但尚未有一种单一的潜在生物标志物或组合在子宫内膜异位症的临床诊断中得到验证。许多研究已经在特定组织中研究了与子宫内膜异位症相关的生物标志物,但缺乏跨组织的综合方法。本综述的目的是基于组织或生物隔室,同时考虑子宫内膜异位症表型(表浅型、卵巢型或深部型,或 rASRM 分期)、月经周期阶段、治疗和症状,提出已鉴定的生物标志物的综合概述。我们在 PubMed 和 Embase 数据库中搜索了符合以下标准的文章:标题中包含“子宫内膜异位症”,并将相关术语“生物标志物”作为医学主题词 (MeSH) 术语或在所有字段中找到。我们仅限于发表在英语和人类人群中的出版物。批判性地分析和讨论了 2005 年 1 月 1 日(当子宫内膜异位症表型开始在论文中描述)至 2022 年 9 月 1 日之间发表的 447 篇关于子宫内膜异位症生物标志物的文章。本综述中包含了 447 篇关于子宫内膜异位症生物标志物的文章,其中包括一个没有子宫内膜异位症的对照组,并提供了关于子宫内膜异位症表型的具体信息。突出显示了存在信息或调整以控制月经周期阶段、症状和治疗的情况,并进一步按生物隔室进行了总结。用于子宫内膜异位症生物标志物研究的 9 个生物隔室的研究频率依次为:外周血、在位内膜、腹腔液、卵巢、尿液、经血、唾液、粪便和宫颈黏液。在所选文章中,分别有 70%、29%、3%和 6%的文章调整了疾病表型、周期阶段、治疗和症状的结果。在这些生物隔室中总共鉴定了 1107 种生物标志物。其中,至少有两个独立的研究小组在 74 种生物标志物中发现了至少两种生物标志物,只有 4 种(TNF-a、MMP-9、TIMP-1 和 miR-451)在至少 3 种组织中被检测到,且这些组织中的队列均有 30 名女性或更多。综合分析是突出寻找临床上相关的子宫内膜异位症生物标志物失败背后的潜在缺陷以及阐明该疾病病理生理学的关键步骤。